Intellia Therapeutics Inc - ESG Rating & Company Profile powered by AI
This Disclosure score covers seventeen United Nations SDGs including: 'Quality Education', 'Decent Work & Economic Growth' and 'Partnerships for the Goals'. The article includes a Q&A section about Intellia Therapeutics Inc. Comprehensive ESG analysis of Intellia Therapeutics Inc are reached by signing up for free.
Intellia Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.5; made up of an environmental score of 2.0, social score of 1.0 and governance score of 4.6.
2.5
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1481 | Tissue Regenix Group PLC | 2.6 | Medium |
1481 | Twist Bioscience Corp | 2.6 | Medium |
1499 | Intellia Therapeutics Inc | 2.5 | Medium |
1499 | Akeso Inc | 2.5 | Medium |
1499 | Allergan plc | 2.5 | Medium |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Intellia Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Does Intellia Therapeutics Inc disclose current and historical energy intensity?
Does Intellia Therapeutics Inc report the average age of the workforce?
Does Intellia Therapeutics Inc reference operational or capital allocation in relation to climate change?
Does Intellia Therapeutics Inc disclose its ethnicity pay gap?
Does Intellia Therapeutics Inc disclose cybersecurity risks?
Does Intellia Therapeutics Inc offer flexible work?
Does Intellia Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Intellia Therapeutics Inc disclose the number of employees in R&D functions?
Does Intellia Therapeutics Inc conduct supply chain audits?
Does Intellia Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Intellia Therapeutics Inc conduct 360 degree staff reviews?
Does Intellia Therapeutics Inc disclose the individual responsible for D&I?
Does Intellia Therapeutics Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Intellia Therapeutics Inc disclose current and / or historical scope 2 emissions?
Does Intellia Therapeutics Inc disclose water use targets?
Does Intellia Therapeutics Inc have careers partnerships with academic institutions?
Did Intellia Therapeutics Inc have a product recall in the last two years?
Does Intellia Therapeutics Inc disclose incidents of discrimination?
Does Intellia Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Has Intellia Therapeutics Inc issued a profit warning in the past 24 months?
Does Intellia Therapeutics Inc disclose parental leave metrics?
Does Intellia Therapeutics Inc disclose climate scenario or pathway analysis?
Does Intellia Therapeutics Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Intellia Therapeutics Inc disclose the pay ratio of women to men?
Does Intellia Therapeutics Inc support suppliers with sustainability related research and development?
Does Intellia Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Intellia Therapeutics Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Intellia Therapeutics Inc involved in embryonic stem cell research?
Does Intellia Therapeutics Inc disclose GHG and Air Emissions intensity?
Does Intellia Therapeutics Inc disclose its waste policy?
Does Intellia Therapeutics Inc report according to TCFD requirements?
Does Intellia Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Intellia Therapeutics Inc disclose energy use targets?
Does Intellia Therapeutics Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Intellia Therapeutics Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Intellia Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.